Skip to content

Arrowhead Research ARWR Other accrued liabilities

Other accrued liabilities at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Royalty Pharma logo
Royalty PharmaRPRX
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
TG Therapeutics logo
TG TherapeuticsTGTX
Charles River Laboratories logo
Charles River LaboratoriesCRL

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's other accrued liabilities?
Arrowhead Research (ARWR) reported other accrued liabilities of $11.21M in Q1 2026.
How has Arrowhead Research's other accrued liabilities changed year-over-year?
Arrowhead Research's other accrued liabilities increased by 2401.1% year-over-year, from $448K to $11.21M.
What is the long-term trend for Arrowhead Research's other accrued liabilities?
Over 4 years (2020 to 2025), Arrowhead Research's other accrued liabilities has grown at a 402.2% compound annual growth rate (CAGR), from $17K to $10.81M.